SFM
FOLD

Sphera Funds Management’s Amicus Therapeutics FOLD Stock Holding History

Sphera Funds Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-300,000
Closed -$2.54M – 100
2016
Q1 		$2.54M Buy
+300,000
New +$2.12M 0.55% 35

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sphera Funds Management's FOLD Position: Q1 2026 in Review

Sphera Funds Management reduced its Amicus Therapeutics (FOLD) stake by 8.4% in Q1 2026, selling an estimated $788K and leaving 603,377 shares worth $8.72M. The position accounts for 1.39% of the portfolio, ranked #14.

Sphera Funds Management first reported a position in FOLD in Q4 2014 and has held it in 30 quarters since. The position peaked at $33.8M in Q1 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Sphera Funds Management held 603,377 shares of Amicus Therapeutics worth $8.72M as of Q1 2026.
  • Sphera Funds Management sold 55,000 Amicus Therapeutics shares in Q1 2026, an estimated $788K.
  • Amicus Therapeutics made up 1.39% of Sphera Funds Management's portfolio in Q1 2026, its #14 holding.
  • Sphera Funds Management first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 30 quarters since.
  • Sphera Funds Management's Amicus Therapeutics position peaked at $33.8M in Q1 2019.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.